secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123252
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim
-------------------------------------------------------------------------------

- GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.
- R&D expenses fell to $26.5M from $45.8M YoY; cash $162.6M sufficient into Q1 2026.
- Evorpacept ASPEN-06 Phase 2 gastric/GEJ cancer showed 40.3% ORR vs 26.6% control; median duration 15.7 months.
- CFO Peter Garcia resigns effective Nov 8; Shelly Pinto (SVP Finance, CAO) appointed interim CFO.
- Upcoming milestones: Phase 3 registrational trial for evorpacept in gastric/GEJ mid-2025; SABCS breast cancer Dec 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/0000950170-24-123252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/alxo-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer